MEDIPOST Co., Ltd. (KOSDAQ:078160)

Market Cap	384.99B +26.9%
Revenue (ttm)	73.90B +2.8%
Net Income	-79.57B
EPS	-2,167.93
Shares Out	39.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	168,054
Open	9,720.00
Previous Close	9,850.00
Day's Range	9,700.00 - 10,270.00
52-Week Range	9,640.00 - 29,100.00
Beta	0.57
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 3, 2026

About MEDIPOST

MEDIPOST Co., Ltd. engages in the cord blood bank business in South Korea and internationally. The company operates through three divisions: Cord Blood Bank, Stem Cell Therapy, and Health Functional Food. It operates cord blood bank under the CELLTREE name. The company also offers CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell products, such as PNEUMOSTEM for the preventative treatment of bronchopulmonary dysplasia. Further, the co...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 322
• Stock Exchange: KOSDAQ
• Ticker Symbol: 078160

Financial Performance

In 2025, MEDIPOST's revenue was 73.66 billion, an increase of 4.25% compared to the previous year's 70.66 billion. Losses were -85.40 billion, 36.6% more than in 2024.